Natco has submitted an ANDA for generic version of Risdiplam – an oral solution for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. The patented drug seems to have done $571mm (~5000 crore INR) of sales in 2023. This patented drug appears to be a competitor to other SMA treatments such as Spinraza and Zolgensma which have sales of approximately $1-1.7 billion in 2023. If Natco’s generic version is approved, it will capture portion of this sales and will potentially improve their topline. If this trend continues, they will be able to offset the potential drop in revlimid sales in the coming years.
Disclosure: Invested
| Subscribe To Our Free Newsletter |
